EXEL
Price
$36.65
Change
-$0.39 (-1.05%)
Updated
Apr 3, 02:37 PM (EDT)
Capitalization
10.37B
40 days until earnings call
MRSN
Price
$0.33
Change
-$0.01 (-2.94%)
Updated
Apr 3, 02:50 PM (EDT)
Capitalization
42.36M
39 days until earnings call
Ad is loading...

EXEL vs MRSN

Header iconEXEL vs MRSN Comparison
Open Charts EXEL vs MRSNBanner chart's image
Exelixis
Price$36.65
Change-$0.39 (-1.05%)
Volume$888
Capitalization10.37B
Mersana Therapeutics
Price$0.33
Change-$0.01 (-2.94%)
Volume$994
Capitalization42.36M
EXEL vs MRSN Comparison Chart
Loading...
EXEL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MRSN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
EXEL vs. MRSN commentary
Apr 03, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is EXEL is a Hold and MRSN is a Hold.

Ad is loading...
COMPARISON
Comparison
Apr 03, 2025
Stock price -- (EXEL: $37.04 vs. MRSN: $0.34)
Brand notoriety: EXEL: Notable vs. MRSN: Not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: EXEL: 70% vs. MRSN: 64%
Market capitalization -- EXEL: $10.37B vs. MRSN: $42.36M
EXEL [@Biotechnology] is valued at $10.37B. MRSN’s [@Biotechnology] market capitalization is $42.36M. The market cap for tickers in the [@Biotechnology] industry ranges from $308.32B to $0. The average market capitalization across the [@Biotechnology] industry is $2.21B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

EXEL’s FA Score shows that 1 FA rating(s) are green whileMRSN’s FA Score has 0 green FA rating(s).

  • EXEL’s FA Score: 1 green, 4 red.
  • MRSN’s FA Score: 0 green, 5 red.
According to our system of comparison, EXEL is a better buy in the long-term than MRSN.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

EXEL’s TA Score shows that 3 TA indicator(s) are bullish while MRSN’s TA Score has 4 bullish TA indicator(s).

  • EXEL’s TA Score: 3 bullish, 4 bearish.
  • MRSN’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, MRSN is a better buy in the short-term than EXEL.

Price Growth

EXEL (@Biotechnology) experienced а +0.08% price change this week, while MRSN (@Biotechnology) price change was -17.12% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -7.84%. For the same industry, the average monthly price growth was -9.88%, and the average quarterly price growth was -14.17%.

Reported Earning Dates

EXEL is expected to report earnings on May 13, 2025.

MRSN is expected to report earnings on May 12, 2025.

Industries' Descriptions

@Biotechnology (-7.84% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
EXEL($10.4B) has a higher market cap than MRSN($42.4M). EXEL YTD gains are higher at: 11.231 vs. MRSN (-76.231). EXEL has higher annual earnings (EBITDA): 719M vs. MRSN (-63.27M). EXEL has more cash in the bank: 1.11B vs. MRSN (135M). MRSN has less debt than EXEL: MRSN (28.6M) vs EXEL (191M). EXEL has higher revenues than MRSN: EXEL (2.17B) vs MRSN (40.5M).
EXELMRSNEXEL / MRSN
Capitalization10.4B42.4M24,528%
EBITDA719M-63.27M-1,136%
Gain YTD11.231-76.231-15%
P/E Ratio21.05N/A-
Revenue2.17B40.5M5,356%
Total Cash1.11B135M823%
Total Debt191M28.6M668%
FUNDAMENTALS RATINGS
EXEL vs MRSN: Fundamental Ratings
EXEL
MRSN
OUTLOOK RATING
1..100
6972
VALUATION
overvalued / fair valued / undervalued
1..100
76
Overvalued
89
Overvalued
PROFIT vs RISK RATING
1..100
22100
SMR RATING
1..100
40100
PRICE GROWTH RATING
1..100
4197
P/E GROWTH RATING
1..100
90100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

EXEL's Valuation (76) in the Biotechnology industry is in the same range as MRSN (89). This means that EXEL’s stock grew similarly to MRSN’s over the last 12 months.

EXEL's Profit vs Risk Rating (22) in the Biotechnology industry is significantly better than the same rating for MRSN (100). This means that EXEL’s stock grew significantly faster than MRSN’s over the last 12 months.

EXEL's SMR Rating (40) in the Biotechnology industry is somewhat better than the same rating for MRSN (100). This means that EXEL’s stock grew somewhat faster than MRSN’s over the last 12 months.

EXEL's Price Growth Rating (41) in the Biotechnology industry is somewhat better than the same rating for MRSN (97). This means that EXEL’s stock grew somewhat faster than MRSN’s over the last 12 months.

EXEL's P/E Growth Rating (90) in the Biotechnology industry is in the same range as MRSN (100). This means that EXEL’s stock grew similarly to MRSN’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
EXELMRSN
RSI
ODDS (%)
Bearish Trend 2 days ago
69%
Bullish Trend 2 days ago
87%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
71%
Bullish Trend 2 days ago
75%
Momentum
ODDS (%)
Bearish Trend 2 days ago
65%
Bearish Trend 2 days ago
88%
MACD
ODDS (%)
Bearish Trend 2 days ago
58%
Bearish Trend 2 days ago
78%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
67%
Bearish Trend 2 days ago
87%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
60%
Bearish Trend 2 days ago
90%
Advances
ODDS (%)
Bullish Trend 15 days ago
65%
Bullish Trend 10 days ago
85%
Declines
ODDS (%)
Bearish Trend 7 days ago
62%
Bearish Trend 3 days ago
89%
BollingerBands
ODDS (%)
N/A
Bullish Trend 2 days ago
82%
Aroon
ODDS (%)
Bullish Trend 2 days ago
57%
Bearish Trend 2 days ago
90%
View a ticker or compare two or three
Ad is loading...
EXEL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MRSN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
PLNT98.773.09
+3.23%
Planet Fitness
RSG244.821.68
+0.69%
Republic Services
KRO7.420.04
+0.54%
Kronos Worldwide
UONEK0.71-0.02
-2.07%
Urban One
ALDX5.32-0.15
-2.74%
Aldeyra Therapeutics

EXEL and

Correlation & Price change

A.I.dvisor indicates that over the last year, EXEL has been loosely correlated with SRPT. These tickers have moved in lockstep 36% of the time. This A.I.-generated data suggests there is some statistical probability that if EXEL jumps, then SRPT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To EXEL
1D Price
Change %
EXEL100%
+1.79%
SRPT - EXEL
36%
Loosely correlated
+0.90%
ALNY - EXEL
34%
Loosely correlated
+4.33%
TECH - EXEL
33%
Poorly correlated
+1.80%
MRSN - EXEL
32%
Poorly correlated
+1.68%
ORMP - EXEL
32%
Poorly correlated
+3.29%
More

MRSN and

Correlation & Price change

A.I.dvisor indicates that over the last year, MRSN has been loosely correlated with IGMS. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if MRSN jumps, then IGMS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MRSN
1D Price
Change %
MRSN100%
+1.68%
IGMS - MRSN
53%
Loosely correlated
+6.96%
INZY - MRSN
50%
Loosely correlated
+6.48%
DYN - MRSN
46%
Loosely correlated
+7.37%
CRNX - MRSN
44%
Loosely correlated
+2.51%
RGNX - MRSN
42%
Loosely correlated
+4.29%
More